Inhibitor Therapeutics, Inc. financial data

Symbol
INTI on OTC
Location
4830 W. Kennedy Blvd., Suite 600, Tampa, FL
State of incorporation
DE
Fiscal year end
December 31
Former names
HedgePath Pharmaceuticals, Inc. (to 8/12/2019), COMMONWEALTH BIOTECHNOLOGIES INC (to 5/20/2013)
Latest financial report
10-K - Q4 2024 - Mar 28, 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 2.87K % -31.6%
Debt-to-equity 91.4 % +87.8%
Return On Equity -94.3 % -107%
Return On Assets -49.3 % -61%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 172M shares +0.17%
Common Stock, Shares, Outstanding 172M shares +0.17%
Entity Public Float 6.6M USD +106%
Common Stock, Value, Issued 17.2K USD +0.17%
Weighted Average Number of Shares Outstanding, Basic 172M shares +0.18%
Weighted Average Number of Shares Outstanding, Diluted 172M shares +0.18%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense 1.68M USD +21.8%
General and Administrative Expense 1.97M USD -2.42%
Operating Income (Loss) -3.66M USD -7.41%
Net Income (Loss) Attributable to Parent -3.34M USD -10.3%
Earnings Per Share, Basic -0.02 USD/shares 0%
Earnings Per Share, Diluted -0.02 USD/shares 0%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 5.61M USD -36.6%
Assets, Current 5.69M USD -36.4%
Assets 5.69M USD -36.4%
Accounts Payable, Current 15.9K USD -52.9%
Accrued Liabilities, Current 694K USD +9.87%
Liabilities, Current 710K USD +6.68%
Liabilities 3.71M USD +1.21%
Retained Earnings (Accumulated Deficit) -52.1M USD -6.85%
Stockholders' Equity Attributable to Parent 1.99M USD -62.4%
Liabilities and Equity 5.69M USD -36.4%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -1.16M USD -52.9%
Net Cash Provided by (Used in) Financing Activities -411K USD -922%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 172M shares +0.17%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -1.16M USD +0.87%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 5.61M USD -36.6%
Deferred Tax Assets, Valuation Allowance 6.29M USD +15.4%
Deferred Tax Assets, Gross 6.29M USD +15.4%
Deferred Tax Assets, Operating Loss Carryforwards 4.04M USD +15%
Additional Paid in Capital 54.1M USD +0.07%